vs

Side-by-side financial comparison of Janus International Group, Inc. (JBI) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Janus International Group, Inc. is the larger business by last-quarter revenue ($219.3M vs $207.3M, roughly 1.1× Ultragenyx Pharmaceutical Inc.). Janus International Group, Inc. runs the higher net margin — 6.9% vs -62.0%, a 69.0% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -4.7%). Janus International Group, Inc. produced more free cash flow last quarter ($8.3M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -8.8%).

Janus Henderson is a British-American global asset management group headquartered in the City of London, United Kingdom. It offers a range of financial products to individuals, intermediary advisors, and institutional investors globally under the trade name Janus Henderson Investors.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

JBI vs RARE — Head-to-Head

Bigger by revenue
JBI
JBI
1.1× larger
JBI
$219.3M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+30.6% gap
RARE
25.9%
-4.7%
JBI
Higher net margin
JBI
JBI
69.0% more per $
JBI
6.9%
-62.0%
RARE
More free cash flow
JBI
JBI
$109.1M more FCF
JBI
$8.3M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-8.8%
JBI

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
JBI
JBI
RARE
RARE
Revenue
$219.3M
$207.3M
Net Profit
$15.2M
$-128.6M
Gross Margin
39.1%
Operating Margin
13.4%
-54.7%
Net Margin
6.9%
-62.0%
Revenue YoY
-4.7%
25.9%
Net Profit YoY
28.8%
3.5%
EPS (diluted)
$0.11
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JBI
JBI
RARE
RARE
Q4 25
$207.3M
Q3 25
$219.3M
$159.9M
Q2 25
$228.1M
$166.5M
Q1 25
$210.5M
$139.3M
Q4 24
$230.8M
$164.6M
Q3 24
$230.1M
$139.5M
Q2 24
$248.4M
$147.0M
Q1 24
$254.5M
$108.8M
Net Profit
JBI
JBI
RARE
RARE
Q4 25
$-128.6M
Q3 25
$15.2M
$-180.4M
Q2 25
$20.7M
$-115.0M
Q1 25
$10.8M
$-151.1M
Q4 24
$300.0K
$-133.2M
Q3 24
$11.8M
$-133.5M
Q2 24
$27.6M
$-131.6M
Q1 24
$30.7M
$-170.7M
Gross Margin
JBI
JBI
RARE
RARE
Q4 25
Q3 25
39.1%
Q2 25
40.9%
Q1 25
38.9%
Q4 24
37.8%
Q3 24
39.6%
Q2 24
43.9%
Q1 24
43.4%
Operating Margin
JBI
JBI
RARE
RARE
Q4 25
-54.7%
Q3 25
13.4%
-106.9%
Q2 25
15.8%
-64.8%
Q1 25
12.0%
-102.6%
Q4 24
5.5%
-74.3%
Q3 24
11.6%
-94.6%
Q2 24
20.8%
-79.1%
Q1 24
21.8%
-151.9%
Net Margin
JBI
JBI
RARE
RARE
Q4 25
-62.0%
Q3 25
6.9%
-112.8%
Q2 25
9.1%
-69.0%
Q1 25
5.1%
-108.5%
Q4 24
0.1%
-80.9%
Q3 24
5.1%
-95.7%
Q2 24
11.1%
-89.5%
Q1 24
12.1%
-156.8%
EPS (diluted)
JBI
JBI
RARE
RARE
Q4 25
$-1.28
Q3 25
$0.11
$-1.81
Q2 25
$0.15
$-1.17
Q1 25
$0.08
$-1.57
Q4 24
$0.01
$-1.34
Q3 24
$0.08
$-1.40
Q2 24
$0.19
$-1.52
Q1 24
$0.21
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JBI
JBI
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$560.8M
$-80.0M
Total Assets
$1.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JBI
JBI
RARE
RARE
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$102.1M
$150.6M
Q2 24
$110.1M
$480.7M
Q1 24
$112.3M
Stockholders' Equity
JBI
JBI
RARE
RARE
Q4 25
$-80.0M
Q3 25
$560.8M
$9.2M
Q2 25
$543.8M
$151.3M
Q1 25
$526.8M
$144.2M
Q4 24
$518.8M
$255.0M
Q3 24
$526.6M
$346.8M
Q2 24
$556.3M
$432.4M
Q1 24
$535.4M
$140.3M
Total Assets
JBI
JBI
RARE
RARE
Q4 25
$1.5B
Q3 25
$1.3B
$1.2B
Q2 25
$1.3B
$1.3B
Q1 25
$1.3B
$1.3B
Q4 24
$1.3B
$1.5B
Q3 24
$1.3B
$1.5B
Q2 24
$1.3B
$1.6B
Q1 24
$1.4B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JBI
JBI
RARE
RARE
Operating Cash FlowLast quarter
$15.0M
$-99.8M
Free Cash FlowOCF − Capex
$8.3M
$-100.8M
FCF MarginFCF / Revenue
3.8%
-48.6%
Capex IntensityCapex / Revenue
3.1%
0.5%
Cash ConversionOCF / Net Profit
0.99×
TTM Free Cash FlowTrailing 4 quarters
$140.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JBI
JBI
RARE
RARE
Q4 25
$-99.8M
Q3 25
$15.0M
$-91.4M
Q2 25
$51.4M
$-108.3M
Q1 25
$48.3M
$-166.5M
Q4 24
$51.4M
$-79.3M
Q3 24
$43.0M
$-67.0M
Q2 24
$31.0M
$-77.0M
Q1 24
$28.6M
$-190.7M
Free Cash Flow
JBI
JBI
RARE
RARE
Q4 25
$-100.8M
Q3 25
$8.3M
$-92.7M
Q2 25
$44.6M
$-110.7M
Q1 25
$41.9M
$-167.8M
Q4 24
$45.3M
$-79.5M
Q3 24
$39.3M
$-68.6M
Q2 24
$25.3M
$-79.0M
Q1 24
$24.0M
$-193.9M
FCF Margin
JBI
JBI
RARE
RARE
Q4 25
-48.6%
Q3 25
3.8%
-58.0%
Q2 25
19.6%
-66.5%
Q1 25
19.9%
-120.5%
Q4 24
19.6%
-48.3%
Q3 24
17.1%
-49.2%
Q2 24
10.2%
-53.7%
Q1 24
9.4%
-178.2%
Capex Intensity
JBI
JBI
RARE
RARE
Q4 25
0.5%
Q3 25
3.1%
0.8%
Q2 25
3.0%
1.5%
Q1 25
3.0%
1.0%
Q4 24
2.6%
0.1%
Q3 24
1.6%
1.2%
Q2 24
2.3%
1.4%
Q1 24
1.8%
3.0%
Cash Conversion
JBI
JBI
RARE
RARE
Q4 25
Q3 25
0.99×
Q2 25
2.48×
Q1 25
4.47×
Q4 24
171.33×
Q3 24
3.64×
Q2 24
1.12×
Q1 24
0.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JBI
JBI

Self Storage New Construction$72.3M33%
Commercial And Others$65.5M30%
Self Storage R3$54.0M25%
Transferred At Point In Time$15.5M7%
Transferred Over Time$12.8M6%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons